Prophylactic Use of Vancomycin in Adult Cardiology and Cardiac Surgery

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 9, Issue 1, 2004, Pages 13-20

  Movahed, Mohammad Reza ^a   Kasravi, Babak ^a   Bryan, Charles S ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiac surgery; Cardiology; Endocarditis; Prophylaxis; Vancomycin

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; CEFAMANDOLE; CEFAZOLIN; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN; DALFOPRISTIN; DAPTOMYCIN; DIPHENHYDRAMINE; HYDROXYZINE; LINEZOLID; NETILMICIN; NORADRENALIN; PENICILLIN G; QUINUPRISTIN; RAMOPLANIN; TEICOPLANIN; VANCOMYCIN;

ANAPHYLAXIS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTIFICIAL HEART PACEMAKER; BACTERIAL ENDOCARDITIS; BACTERIAL STRAIN; CARDIOLOGY; CLINICAL TRIAL; DEFIBRILLATOR; DOSIMETRY; DRUG ACTIVITY; DRUG EFFICACY; DRUG ERUPTION; DRUG INDICATION; DRUG TOLERABILITY; DRUG TOXICITY; DRUG USE; EDEMA; ENDOCARDITIS; ENTEROCOCCUS; FLUSHING; HEART ARREST; HEART CATHETERIZATION; HEART SURGERY; HEART VALVE PROSTHESIS; HEART VALVE REPLACEMENT; HUMAN; HYPOTENSION; INCIDENCE; INFECTION PREVENTION; LUNG EDEMA; META ANALYSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MUSCLE SPASM; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; OLIGURIA; OPEN HEART SURGERY; OTOTOXICITY; PENICILLIN ALLERGY; PHLEBITIS; POSTOPERATIVE CARE; POSTOPERATIVE INFECTION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PRURITUS; RED MAN SYNDROME; REVIEW; SIDE EFFECT; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS INFECTION; SURGICAL INFECTION; SYNDROME; THORAX PAIN; TRANSESOPHAGEAL ECHOCARDIOGRAPHY;

EID: 1942510405     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/107424840400900i103     Document Type: Review

References (92)

1. Moellering RC Jr. Vancomycin resistant enterococci. Clin Infect Dis 26:1196-1199, 1998
2. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 340:493-501, 1999
3. Garrett DO, Jochimsen E, Murfitt K, et al. The emergence of decreased susceptibility to vancomycin in Staphylococcus epidermidis. Infect Control Hosp Epidemiol 20:167-170, 1990
4. Moellering RC Jr. Linezolid: The first oxazolidone antimicrobial. Ann Intern Med 138:135-142, 2003
5. Eliopoulos GM. Quinupristin-dalfopristin and linezolid: Evidence and opinion. Clin Infect Dis 36:473-478, 2003
6. Kirst HA, Thompson DG, Nicas TI. Historical yearly usage of vancomycin. Antimicrob Agents Chemother 42:1303-1304, 1998
7. Hospital Infection Control Practices Advisory Committee. Recommendations for preventing the spread of vancomycin resistance: Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC) Am J Infect Control 23:87-94, 1995
8. Belliveau PP, Rothman AL, Maday CE. Limiting vancomycin use to combat vancomycin- resistant Enterococcusfaecium. Am J Health-Syst Pharm 53:1570-1575, 1996
9. Cunha BA. Vancomycin. Med Clin N Am 79:817-831, 1996
10. Hermans FE, Wilhelm MF. Vancomycin. Mayo Clin Proc 62:901-905, 1987
11. Moellering RC Jr. The specter of glycopeptide resistance: Current trends and future considerations. Am J Med 104 (5A):3S-6S, 1998
12. Cosgrove SE, Sakoulas G, Perencevich EN, et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: A meta-analysis. Clin Infect Dis 36:53-59, 2003
13. Gopal V, Bisno AL, Silverblatt FJ. Failure of vancomycin treatment in Staphylococcus aureus endocarditis. JAMA 234:1604-1606, 1976
14. Small MP, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 34:1227-1231, 1990
15. Cantoni L, Glauser MP, Bille J. Comparative efficacy of daptomycin, vancomycin, and cloxacillin for the treatment of Staphylococcus aureus endocarditis in rats and role of test conditions in this determination. Antimicrob Agents Chemother 34:2348-2353, 1990
16. Kernodle DS, Kaiser AB. Comparative prophylactic efficacy of cefazolin and vancomycin a guinea pig model of Staphylococcus aureus wound infection. J Infect Dis 168:152-157, 1993
17. Mayhew JF, Deutsch S. Cardiac arrest following administration of vancomycin. Can Anaesth Soc J 32:65-66, 1985
18. Glicklich D, Figura I. Vancomycin and cardiac arrest. Ann Intern Med 101:880-881, 1984
19. Levy JH, Kettlekamp N, Goertz P, et al. Histamine release by vancomycin: A mechanism for hypotension in man. Anesthesiology 67:122-125, 1987
20. Wallace MR, Mascola JR, Oldfield EC III. Red man syndrome: Incidence, etiology, and prophylaxis. J Infect Dis 164:1180-1185, 1991
21. Sahai J, Healy DP, Garris R, et al. Influence of antihistamine pretreatment on vancomycin- induced red-man syndrome. J Infect Dis 160:876-878, 1989
22. Symons NL, Hobbes AF, Leaver HK. Anaphylactoid reactions to vancomycin during anesthesia: Two clinical reports. Can Anaesth Soc J 32:178-181, 1985
23. Valero R, Gomar C, Fita G, et al. Adverse reactions to vancomycin prophylaxis in cardiac surgery. J Cardiothoracic Vasc Anesth 5:574-576, 1991
24. Romanelli VA, Howie MB, Myerowitz PD, et al. Intraoperative and postoperative effects of vancomycin administration in cardiac surgery patients: A prospective, double-blind, randomized trial. Crit Care Med 21:1124-1131, 1993
25. Baraka A, Taha S, Bijjani A, et al. Administration of vancomycin during cardiopulmonary bypass. Anesthesia 47:1086-1087, 1992
26. Rosenberg JM, Wahr JA, Smith KA. Effect of vancomycin infusion on cardiac function in patients scheduled for cardiac operation. J Thorac Cardiovasc Surg 109:561-565, 1995
27. Farber BF, Karchmer AW, Buckley MJ, et al. Vancomycin prophylaxis in cardiac operations: Determination of an optimal dosage regimen. J Thorac Cardiovasc Surg 85:933-935, 1983
28. Austin TW, Leake J, Coles JC, et al. Vancomycin blood levels during cardiac bypass surgery. Can J Surg 24:423-425, 1981
29. The Medical Letter. Antimicrobial prophylaxis in surgery. Medical Letter 39:97-100, 1997
30. Maki DG, Bohn MJ, Stoltz SM, et al. Comparative study of cefazolin, cefamandole, and vancomycin for surgical prophylaxis in cardiac and vascular operations. A double-blind randomized trial. J Thoracic Cardiovasc Surg 104:1423-1434, 1992
31. Finkelstein R, Rabino G, Mashiah T, et al. Vancomycin versus cefazolin prophylaxis for cardiac surgery in the setting of a high prevalence of methicillin-resistant staphylococcal infections. J Thorac Cardiovasc Surg 123:326-332, 2002
32. Miglioli PA, Merlo F, Grabocka E, et al. Effects of cardiopulmonary bypass on vancomycin plasma concentration decay. Pharmacol Research 38:275-278, 1998
33. Kitzes-Cohen R, Farin D, Piva G, et al. Pharmacokinetics of vancomycin administered as prophylaxis before cardiac surgery. Ther Drug Monit 22:661-667, 2000
34. Vuorisalo S, Pokela R, Syrjala H. Is single-dose antibiotic prophylaxis sufficient for coronary artery bypass surgery? An analysis of peri- and post-operative serum cefuroxime and vancomycin levels. J Hosp Infect 37:237-247, 1997
35. Ducharme MP, Slaughter RL, Edwards DJ. Vancomycin pharmacokinetics in a patient population: Effect of age, gender, and body weight. Ther Drug Monit 16:513-518, 1994
36. Vance-Bryan K, Guay DR, Gilliland SS, et al. Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique. Antimicrob Agents Chemother 37:436-440, 1993
37. Wurtz R, Itokazu G, Rodvold K. Antimicrobial dosing in obese patients. Clin Infect Dis 25:112-118, 1997
38. Cantu TG, Yamanaka-Yuen NA, Lietman PS. Serum vancomycin concentrations: Reappraisal of their clinical value. Clin Infect Dis 18:533-543, 1994
39. Moellering RC. Monitoring serum vancomycin levels: Climbing the mountain because it there? (editorial). Clin Infect Dis 18:544-546, 1994
40. Saunders NJ. Why monitor peak vancomycin concentrations? Lancet 344:1748-1750, 1994
41. Douglas OR. Antimicrobial prophylaxis in Adults. Mayo Clin Proc 75:98-109, 2000
42. Dajani AS, Taubert KA, Wilson W, et al. Prevention of bacterial endocarditis: Recommendations by American Heart Association. JAMA 277:1794-1801, 1997
43. Baddour LM, Hill MM, Felty-Duckworth AM. Antimicrobial prophylaxis of experimental endocarditis caused by Staphylococcus epidermidis. Infection 17:90-96, 1989
44. Wheat LJ, Smith JW, Reynolds J, et al. Comparison of cefazolin, cefamandole, vancomycin, and LY 146032 for prophylaxis of experimental Staphylococcus epidermidis endocarditis. Antimicrob Agents Chemother 32:63-67, 1988
45. Massias L, Dubois C, de Lentdecker P, et al. Penetration of vancomycin in uninfected sternal bone. Antimicrob Agents Chemother 36:2539-2541, 1992
46. Martin C, Alaya M, Mallet M-N, et al. Penetration of vancomycin into mediastinal and cardiac tissues in humans. Antimicrob Agents Chemother 38:396-399, 1994
47. Rupp ME, Archer GL. Coagulase-negative staphylococci: Pathogens associated with medical progress. Clin Infect Dis 19:231-245, 1994
48. Antunes MJ, Sanches MF, Fernandes LE. Antibiotic prophylaxis and prosthetic valve endocarditis. J Heart Valve Dis 1:201-205, 1992
49. Goldmann DA, Hopkins CC, Karchmer AW, et al. Cephalothin prophylaxis in cardiac valve surgery: A prospective, double-blind comparison of two-day and six-day regimens. J Thorac Cardiovasc Surg 73:470-479, 1977
50. Niederhauser U, Vogt M, Vogt P, et al. Cardiac surgery in a high-risk group of patients: Is prolonged postoperative antibiotic prophylaxis effective? J Thorac Cardiovasc Surg 114:162-168, 1997
51. Bryan CS, Smith CW, Sutton JP, et al. Comparison of cefamandole and cefazolin during cardiopulmonary bypass. J Thorac Cardiovasc Surg 86:222-225, 1983
52. Doebbeling BN, Pfaller MA, Kuhns KR, et al. Cardiovascular surgery prophylaxis: A randomized, controlled comparison of cefazolin and cefuroxime. J Thorac Cardiovasc Surg 99:981-989, 1990
53. Kaiser AB, Petracek MR, Lea IV, et al. Efficacy of cefazolin, cefamandole, and gentamicin as prophylactic agents in cardiac surgery: Results of a prospective, randomized, double-blind trial in 1030 patients. Ann Surg 206:791-797, 1987
54. Joyce FS, Szczepanski KP. A double-blind comparative study of prophylactic antibiotic therapy in open heart surgery: Penicillin G versus vancomycin. Thorac Cardiovasc Surg 34:100-103, 1986
55. Vuorisalo S, Pokela R, Syrjala H. Comparison of vancomycin and cefuroxime for infection prophylaxis in coronary artery bypass surgery. Infect Control Hosp Epidemiol 19:234-239, 1998
56. Salminen US, Viljanen TU, Valtonen VV, et al. Ceftriaxone versus vancomycin prophylaxis in cardiovascular surgery. J Antimicrob Chemother 44:287-290, 1999
57. Pear SM, Goldsmith DL, Williamson TH, et al. Identification and voluntary reduction of vancomycin use for perioperative antibiotic prophylaxis during coronary artery bypass graft surgery. Infect Control Hosp Epidemiol 19:513-515, 1998
58. Roy MC. Surgical-site infections after coronary artery bypass graft surgery: Discriminating site-specific risk factors to improve prevention efforts. Infect Control Hosp Epidemiol 19:229-233, 1998
59. The Medical Letter. Antimicrobial prophylaxis in surgery. Medical Letter 39:97-102, 1997
60. Victor F, de Place C, Leclercq C, et al. [Infections on permanent endocavitary pacemaker leads: Value of transesophageal echocardiography] Arch Mal Coeur Vaiss. 88(12):1875-1881, 1995
61. Klug D, Lacroix D, Savoye C, et al. Systemic infection related to endocarditis on pacemaker leads: Clinical presentation and management. Circulation 95:2098-2107, 1997
62. Arber N, Pras E, Copperman Y, et al. Pacemaker endocarditis. Report of 44 cases and review of the literature. Medicine 73:299-305, 1994
63. Hartstein AI, Jackson J, Gilbert DN. Prophylactic antibiotics and the insertion of permanent transvenous cardiac pacemakers. J Thorac Cardiovasc Surg 75:219-223, 1978
64. Chauhan A, Grace AA, Newell SA, et al. Early complications after dual chamber versus single chamber pacemaker implantation. PACE 17:2012-2015, 1994
65. Muers MF, Arnold AG, Sleight P. Prophylactic antibiotics for cardiac pacemaker implantation. A prospective trial. Br Heart J 46:539-544, 1981
66. Bluhm G, Jacobson B, Julander I, et al. Antibiotic prophylaxis in pacemaker surgery. A prospective study. Scand J Thorac Cardiovasc Surg 18:227-234, 1984
67. Ramsdale DR, Charles RG, Rowlands DB, et al. Antibiotic prophylaxis for pacemaker implantation: a prospective randomized trial. Pacing Clin Electrophysiol 7:844-849, 1984
68. Mounsey JP, Griffith MJ, Tynan M, et al. Antibiotic prophylaxis in permanent pacemaker implantation: A prospective randomized trial. Br Heart J 72:339-343, 1994
69. Bru P, Cointe R, Metge M, et al. [Value of systematic preventive antibiotherapy in cardiac pacemaker implantation] Ann Cardiol Angeiol (Paris) 40(4):171-174, 1991
70. Da Costa A, Kirkorian G, Cucherat M, et al. Antibiotic prophylaxis for permanent pacemaker implantation: A meta-analysis. Circulation 97:1796-1801, 1998
71. Bakker PFA, Hauer RNW, Wever EFD. Infections involving implanted cardioverter defibrillator devices. PACE 15:654-658, 1992
72. Shea KW, Schwartz RK, Gambino AT, et al. Bacteremia associated with percutaneous trans luminal coronary angioplasty. Cathet Cardiovasc Diagn 36:5-9, 1995
73. Samore MH, Wessolossky MA, Lewis SM, et al. Frequency, risk factors, and outcome for bacteremia after percutaneous transluminal coronary angioplasty. Am J Cardiol 79:873-877, 1997
74. Timsit JF, Wolff MA, Bedos JP, et al. Cardiac abscess following percutaneous transluminal coronary angioplasty. Chest 103:639-641, 1993
75. Cleveland KO, Gelfand MS. Invasive staphylococcal infections complicating percutaneous transluminal coronary angioplasty: Three cases and review. Clin Infect Dis 21:93-96, 1995
76. Malanoski GJ, Samore MH, Pefanis A, et al. Staphylococcus aureus catheter-associated bacteremia. Minimal effective therapy and unusual infectious complications associated with arterial sheath catheters. Arch Intern Med 155:1161-1166, 1995
77. McCready RA, Siderys H, Pittman JN, et al. Septic complications after cardiac catheterization and percutaneous transluminal coronary angioplasty. J Vasc Surg 14:170-174, 1991
78. Roudaut R, Lartigue MC, Texier-Maugein J, et al. Incidence of bacteremia or fever during transesophageal echocardiography: a prospective study of 82 patients. Eur Heart J 14:936-940, 1993
79. Shyu KG, Hwang JJ, Lin SC, et al. Prospective study of blood culture during transesophageal echocardiography. Am Heart J 124:1541-1544, 1992
80. Nikutta P, Mantey-Stiers F, Becht I, et al. Risk of bacteremia induced by transesophageal echocardiography: Analysis of 100 consecutive procedures. J Am Soc Echocardiogr 5:168-172, 1992
81. Melendez LJ, Chan KL, Cheung PK, et al. Incidence of bacteremia in transesophageal echocardiography: A prospective study of 140 consecutive patients. J Am Coll Cardiol 18:1650-1654, 1991
82. Pongratz G, Henneke KH, von der Grun M, et al. Risk of endocarditis in transesophageal echocardiography. Am Heart J 125:190-193, 1993
83. Phillips E, Louie M, Knowles SR, et al. Cost-effectiveness analysis of six strategies for cardiovascular surgery prophylaxis in patients labeled penicillin allergic. Am J Health Syst Pharm 57:339-345, 2000
84. Wenzel RP, Reagan DR, Bertino JS, et al. Methicillin-resistant Staphylococcus aureus outbreak: A consensus panel's definition and management guidelines. Am J Infect Control 26:102-110, 1998
85. Lipsky BA, Baker CA, McDonald LL, et al. Improving the appropriateness of vancomycin use by sequential interventions. Am J Infect Control 27:84-91, 1999
86. Richardson LP, Wiseman SW, Malani PN, et al. Effectiveness of a vancomycin restriction policy in changing the prescribing patterns of house staff. Microb Drug Resist 6:327-330, 2000
87. Thomas AR, Cieslak PR, Strausbaugh LJ, et al. Effectiveness of pharmacy policies designed to limit inappropriate vancomycin use: A population-based assessment. Infect Control Hosp Epidemiol 23:683-688, 2002
88. Schentag JJ, Hyatt JM, Carr JR, et al. Genesis of methicillin-resistant Staphylococcus aureus (MRSA), how treatment of MRSA infections has selected for vancomycin-resistant Enterococcus faecium, and the importance of antibiotic management and infection control. Clin Infect Dis 26:1204-1214, 1998
89. Zanetti G, Goldie SJ, Platt R. Clinical consequences and cost of limiting use of vancomycin for perioperative prophylaxis: Example of coronary artery bypass surgery. Emerg Infect Dis 7:820-827, 2001
90. Spelman D, Harrington G, Russo P, et al. Clinical, microbiological, and economic benefit of a change in antibiotic prophylaxis for cardiac surgery. Infect Control Hosp Epidemiol 23:402-404, 2002
91. Mini E, Nobili S, Periti P. Does surgical prophylaxis with teicoplanin constitute a therapeutic advance? J Chemother 12(Suppl 5):40-55, 2000
92. Codina C, Miro JM, Tuset M, et al. [Vancomycin and teicoplanin use as antibiotic prophylaxis in cardiac surgery: Pharmacoeconomic study]. Med Clin (Barc) 14(suppl 3):54-61, 2000